Description of the Ability to Learn How to Handle Inhaler Devices in COPD
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the world and further increase in its prevalence and mortality has been predicted. Currently, the main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination: * long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone), * long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium). These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®, Handihaler® and Diskus®.
• Male or female aged more than 40 years,
• Written informed consent,
• Diagnosis of COPD according to international guidelines (GOLD 2012),
• Social security or health insurance,
• Women of childbearing potential with a very effective contraception according to the Haute Autorité de Santé (HAS) recommendations.